|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christian Marcazzo explains how adopting a new kind of data strategy might be disruptive to the expectation of how biologics development is carried out — but it may also be transformational.
|
|
|
Angelos Stergiou, PhD, explains how the COVID-19 pandemic saw failures in the healthcare delivery system not only in general medicine, but also specifically in oncology. At the same time, several opportunities came to light during such a difficult, frightening moment, bringing a number of large- and small-scale innovations forth.
|
|
|
Dr. Joseph F. Bristow, Chief Technology Officer for Kytosan USA, discusses chitosan and its impact on the pharmaceutical industry, as well as Kytosan USA’s production plans.
|
|
|
Mariana Nacht, PhD, reviews a new gene editing approach that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of the gene (or transgene) at a precise spot in a patient’s genome.
|
|
|
|
|
|
|
|
|

Micropore Technologies is a global process technology and service provider to the pharmaceutical industry featuring patented crossflow mixing equipment for the commercially scalable development of microspheres, nanoparticles, and emulsions used in a wide range of controlled release, sterile injectable drug products. Originally spun-out of Loughborough University’s internationally renowned chemical engineering department, the company’s global headquarters and technical center are located in Wilton Center, UK with offices and operations in the USA, India, South Korea & Japan supporting over a hundred clients and strategic partners. Click here for more.


Lyophilization Technology, Inc. (LTI) is a Contract Development & Manufacturing Organization (CDMO) focused on all aspects of lyophilization for preparation of health care products. Clients leverage on our abilities for bringing new products to the clinic and implementing improvements for current products. Capitalize on over 25 years of excellence and our unparalleled capabilities in product development, process engineering, clinical manufacturing, and technical support. Click here for more.
|
|
|
|
|
|
 |
|
Evonik recently announced it now offers EUDRATEC SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products…..
|
|
 |
|
Novartis recently announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three….
|
|
 |
|
Adaptive Research and UBERDOC recently announced a collaboration to expand clinical trial access to the physicians and clinical trial sites….
|
|
 |
|
Agenus and Targovax ASA recently announced they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines with Agenus´s clinically validated….
|
|
|
|
|
|
|
|
 |
|
This webinar will explore how to conduct effective extractables and leachables (E&L) testing on plastic process materials used during pharmaceutical and biopharmaceutical manufacturing…..
|
|
 |
|
Emergent and groniger partner to present the benefits and features of the INTEGRA® high-speed aseptic fill line with isolator technology for viral vaccines and therapeutics.
|
|
 |
|
The need for flexible solutions for potent product handling is increasing. We’ll discuss the proven benefits of aseptic isolator systems in sterile environments and take a look at real feedback from real customers of ours in an upcoming webinar on Tuesday, November 16th at 11:00 AM EST.
|
|
|
|
|
|
|
|
 |
|
What techniques should manufacturers employ when working with low-dose drug products?
By: Thomas Daggs, MBA, Vice President, Product Development & Quality Control, and Angelo Consalvo, Director of Manufacturing, Enteris BioPharma
Anyone who takes an oral tablet medication – whether prescribed …
|
|
 |
|
Antibody production is a multi-step complex process and generating reproducible antibodies is highly critical for immunoassays-based research, immunodiagnostics, and immunotherapy. Antibodies’ reproducibility is driven by their specificity and several other factors ranging from antibody design to target validation. Our Antibody …
|
|
 |
|
By: Alexandra H. Heussner, PhD, Laboratory Manager ASL, and Melanie Zerulla-Wernitz, PhD, Head of ASL, Development Service, Vetter Pharma-Fertigung GmbH & Co. KG
In the pharmaceutical manufacturing process, a relatively new class of parenteral drug products on the market – …
|
|
|
|
|
Upcoming eNewsletter Features:
March 23 – Parenteral Contract Manufacturing
March 30 – Polymers & Biomaterials
|
|
|
|
|
|
|
|